Biogen Downgraded by Baird Analyst Over Move to Salvage Alzheimer’s Drug

(Bloomberg) -- Biogen Inc. suffered another bearish sell-side call as Robert W. Baird analyst Brian Skorney cut his rating and warned investors ahead of a company presentation at a medical meeting ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.